Sequencing overview of Ewing sarcoma: A journey across genomic, epigenomic and transcriptomic landscapes

International Journal of Molecular Sciences

Volumn 16, Issue 7, 2015, Pages 16176-16215

  Sand, Laurens G L ^a   Szuhai, Karoly ^a   Hogendoorn, Pancras C W ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Bone neoplasm; Bone tumor; Epigenetics; Ewing sarcoma; Immunotherapy; Micro environment; Next generation sequencing; Soft tissue tumor; Splicing; Targeted therapy

Indexed keywords

BRCA2 PROTEIN; CD99 ANTIGEN; CHEMOKINE RECEPTOR CXCR4; CYCLIN D1; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 3; ETOPOSIDE; GAMMA INTERFERON; IFOSFAMIDE; IRINOTECAN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; NUCLEAR RECEPTOR DAX 1; PROTEIN MDM2; PROTEIN P53; TEMOZOLOMIDE; TRABECTEDIN; TRANSCRIPTION FACTOR E2F3; TRANSCRIPTION FACTOR EZH2; TRANSCRIPTION FACTOR GLI1; TRANSCRIPTION FACTOR NKX2.2; TRANSCRIPTOME; VASCULOTROPIN A; VINCRISTINE; ONCOPROTEIN;

CANCER CHEMOTHERAPY; CELL PROLIFERATION; CHROMATIN ASSEMBLY AND DISASSEMBLY; CHROMATIN IMMUNOPRECIPITATION; CHROMOSOME 8; COPY NUMBER VARIATION; DNA DAMAGE; DNA REPAIR; DOWN REGULATION; EPIGENETICS; EWING SARCOMA; GENE AMPLIFICATION; GENE DELETION; GENE FREQUENCY; GENE MAPPING; GENE MUTATION; GENE SEQUENCE; GENE TRANSLOCATION; GENOMICS; HUMAN; IMMUNOTHERAPY; MICROARRAY ANALYSIS; PROTEIN EXPRESSION; REVIEW; RHABDOMYOSARCOMA; TUMOR GROWTH; UPREGULATION; DNA SEQUENCE; GENETICS; METABOLISM; MOLECULARLY TARGETED THERAPY; SARCOMA, EWING;

EPIGENOMICS; HUMANS; MOLECULAR TARGETED THERAPY; ONCOGENE PROTEINS, FUSION; SARCOMA, EWING; SEQUENCE ANALYSIS, DNA; TRANSCRIPTOME;

EID: 84937484985     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms160716176     Document Type: Review

References (227)

1. De Alava, E., Lessnick, S.L., Sorensen, P.H. Ewing Sarcoma in WHO Classification of Tumours of Soft Tissue and Bone, 4th ed., Fletcher, C.D.M., Bridge, J.A., Hogendoorn, P.C.W., Mertens, F., Eds., IARC: Lyon, France, 2013, pp. 306–309.
2. Le Deley, M.-C., Delattre, O., Schaefer, K.-L., Burchill, S.A., Koehler, G., Hogendoorn, P.C.W., Lion, T., Poremba, C., Marandet, J., Ballet, S., et al. Impact of EWS-ETS fusion type on disease progression in Ewingʼs sarcoma/peripheral primitive neuroectodermal tumor: Prospective results from the cooperative Euro-E.W.I.N.G. 99 trial. J. Clin. Oncol. 2010, 28, 1982–1988.
3. Pierron, G., Tirode, F., Lucchesi, C., Reynaud, S., Ballet, S., Cohen-Gogo, S., Perrin, V., Coindre, J.-M., Delattre, O. A new subtype of bone sarcoma defined by BCOR-CCNB3 gene fusion. Nat. Genet. 2012, 44, 461–466.
4. Graham, C., Chilton-MacNeill, S., Zielenska, M., Somers, G.R. The CIC-DUX4 fusion transcript is present in a subgroup of pediatric primitive round cell sarcomas. Hum. Pathol. 2012, 43, 180–189.
5. Szuhai, K., IJszenga, M., de Jong, D., Karseladze, A., Tanke, H.J., Hogendoorn, P.C.W. The nfatc2 gene is involved in a novel cloned translocation in a Ewing sarcoma variant that couples its function in immunology to oncology. Clin. Cancer Res. 2009, 15, 2259–2268.
6. Jawad, M.U., Cheung, M.C., Min, E.S., Schneiderbauer, M.M., Koniaris, L.G., Scully, S.P. Ewing sarcoma demonstrates racial disparities in incidence-related and sex-related differences in outcome. Cancer 2009, 115, 3526–3536.
7. Zucman-Rossi, J., Batzer, M.A., Stoneking, M., Delattre, O., Thomas, G. Interethnic polymorphism of EWS intron 6: Genome plasticity mediated by alu retroposition and recombination. Hum. Genet. 1997, 99, 357–363.
8. Kolomietz, E., Meyn, M.S., Pandita, A., Squire, J.A. The role of Alu repeat clusters as mediators of recurrent chromosomal aberrations in tumors. Genes Chromosomes Cancer 2002, 35, 97–112.
9. Worch, J., Cyrus, J., Goldsby, R., Matthay, K.K., Neuhaus, J., DuBois, S.G. Racial differences in the incidence of mesenchymal tumors associated with EWSR1 translocation. Cancer 2011, 20, 449–453.
10. Postel-Vinay, S., Veron, A.S., Tirode, F., Pierron, G., Reynaud, S., Kovar, H., Oberlin, O., Lapouble, E., Ballet, S., Lucchesi, C., et al. Common variants near TARDBP and EGR2 are associated with susceptibility to Ewing sarcoma. Nat. Genet. 2012, 44, 323–327.
11. Monument, M.J., Johnson, K.M., McIlvaine, E., Abegglen, L., Watkins, W.S., Jorde, L.B., Womer, R.B., Beeler, N., Monovich, L., Lawlor, E.R., et al. Clinical and biochemical function of polymorphic nr0b1 GGAA-microsatellites in Ewing sarcoma: A report from the childrenʼs oncology group. PLoS ONE 2014, 9, e104378.
12. Beck, R., Monument, M.J., Watkins, W.S., Smith, R., Boucher, K.M., Schiffman, J.D., Jorde, L.B., Randall, R.L., Lessnick, S.L. EWS/FLI-responsive ggaa microsatellites exhibit polymorphic differences between european and african populations. Cancer Genet. 2012, 205, 304–312.
13. Kovar, H.: Context matters: The hen or egg problem in Ewingʼs sarcoma. Semin. Cancer Biol. 2005, 15, 189–196.
14. Andersson, M.K., Ståhlberg, A., Arvidsson, Y., Olofsson, A., Semb, H., Stenman, G., Nilsson, O., Åman, P. The multifunctional FUS, EWS and TAF15 proto-oncoproteins show cell type-specific expression patterns and involvement in cell spreading and stress response. BMC Cell Biol. 2008, 9, 37–37.
15. Kwon, I., Kato, M., Xiang, S., Wu, L., Theodoropoulos, P., Mirzaei, H., Han, T., Xie, S., Corden, J.L., McKnight, S.L. Phosphorylation-regulated binding of rna polymerase ii to fibrous polymers of low complexity domains. Cell 2013, 155, 1049–1060.
16. Kim, K.Y., Hwang, Y.J., Jung, M.K., Choe, J., Kim, Y., Kim, S., Lee, C.J., Ahn, H., Lee, J., Kowall, N.W., et al. A multifunctional protein ews regulates the expression of drosha and micrornas. Cell Death Differ. 2014, 21, 136–145.
17. Park, J.H., Kang, H.J., Kang, S.I., Lee, J.E., Hur, J., Ge, K., Mueller, E., Li, H., Lee, B.-C., Lee, S.B. A multifunctional protein ews is essential for early brown fat lineage determination. Dev. Cell 2013, 26, 393–404.
18. Riggi, N., Suvà, M.-L., Suvà, D., Cironi, L., Provero, P., Tercier, S., Joseph, J.-M., Stehle, J.-C., Baumer, K., Kindler, V., et al. EWS-FLI-1 expression triggers a Ewingʼs sarcoma initiation program in primary human mesenchymal stem cells. Cancer Res. 2008, 68, 2176–2185.
19. Tanaka, M., Yamazaki, Y., Kanno, Y., Igarashi, K., Aisaki, K.-I., Kanno, J., Nakamura, T. Ewing’s sarcoma precursors are highly enriched in embryonic osteochondrogenic progenitors. J. Clin. Investig. 2014, 124, 3061–3074.
20. Lessnick, S.L., Dacwag, C.S., Golub, T.R. The Ewingʼs sarcoma oncoprotein EWS/FLI induces a p53-dependent growth arrest in primary human fibroblasts. Cancer Cell 2002, 1, 393–401.
21. Miyagawa, Y., Okita, H., Nakaijima, H., Horiuchi, Y., Sato, B., Taguchi, T., Toyoda, M., Katagiri, Y.U., Fujimoto, J., Hata, J.-I., et al. Inducible expression of chimeric EWS/ETS proteins confers Ewingʼs family tumor-like phenotypes to human mesenchymal progenitor cells. Mol. Cell. Biol. 2008, 28, 2125–2137.
22. Riggi, N., Suvà, M.-L., de Vito, C., Provero, P., Stehle, J.-C., Baumer, K., Cironi, L., Janiszewska, M., Petricevic, T., Suvà, D., et al. EWS-FLI-1 modulates miRNA145 and SOX2 expression to initiate mesenchymal stem cell reprogramming toward Ewing sarcoma cancer stem cells. Genes Dev. 2010, 24, 916–932.
23. Torchia, E.C., Boyd, K., Rehg, J.E., Qu, C., Baker, S.J. EWS/FLI-1 induces rapid onset of myeloid/erythroid leukemia in mice. Mol. Cell. Biol. 2007, 27, 7918–7934.
24. Leacock, S.W., Basse, A.N., Chandler, G.L., Kirk, A.M., Rakheja, D., Amatruda, J.F. A zebrafish transgenic model of Ewing’s sarcoma reveals conserved mediators of EWS-FLI1 tumorigenesis. Dis. Models Mech. 2012, 5, 95–106.
25. Von Levetzow, C., Jiang, X., Gwye, Y., von Levetzow, G., Hung, L., Cooper, A., Hsu, J.H.-R., Lawlor, E.R. Modeling initiation of Ewing sarcoma in human neural crest cells. PLoS ONE 2011, 6, e19305.
26. Brohl, A.S., Solomon, D.A., Chang, W., Wang, J., Song, Y., Sindiri, S., Patidar, R., Hurd, L., Chen, L., Shern, J.F., et al. The genomic landscape of the Ewing sarcoma family of tumors reveals recurrent stag2 mutation. PLoS Genet. 2014, 10, e1004475.
27. Tirode, F., Surdez, D., Ma, X., Parker, M., Le Deley, M.C., Bahrami, A., Zhang, Z., Lapouble, E., Grossetête-Lalami, S., Rusch, M., et al. Genomic landscape of Ewing sarcoma defines an aggressive subtype with co-association of stag2 and tp53 mutations. Cancer Discov. 2014, 4, 1342–1353.
28. Crompton, B.D., Stewart, C., Taylor-Weiner, A., Alexe, G., Kurek, K.C., Calicchio, M.L., Kiezun, A., Carter, S.L., Shukla, S.A., Mehta, S.S., et al. The genomic landscape of pediatric Ewing sarcoma. Cancer Discov. 2014, 4, 1326–1341.
29. Lawrence, M.S., Stojanov, P., Polak, P., Kryukov, G.V., Cibulskis, K., Sivachenko, A., Carter, S.L., Stewart, C., Mermel, C.H., Roberts, S.A., et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 2013, 499, 214–218.
30. Jiang, Y., Subbiah, V., Janku, F., Ludwig, J.A., Naing, A., Benjamin, R.S., Brown, R.E., Anderson, P., Kurzrock, R. Novel secondary somatic mutations in Ewingʼs sarcoma and desmoplastic small round cell tumors. PLoS ONE 2014, 9, e93676.
31. Riggi, N., Knoechel, B., Gillespie, S.M., Rheinbay, E., Boulay, G., Suvà Mario, L., Rossetti, N.E., Boonseng, W.E., Oksuz, O., Cook, E.B., et al. EWS-FLI1 utilizes divergent chromatin remodeling mechanisms to directly activate or repress enhancer elements in Ewing sarcoma. Cancer Cell 2014, 26, 668–681.
32. Tomazou, E.M., Sheffield, N.C., Schmidl, C., Schuster, M., Schönegger, A., Datlinger, P., Kubicek, S., Bock, C., Kovar, H. Epigenome mapping reveals distinct modes of gene regulation and widespread enhancer reprogramming by the oncogenic fusion protein EWS-FLI 1. Cell Rep. 2015, 10, 1082–1095.
33. Consortium, T.E.P. The encode (encyclopedia of DNA elements) project. Science 2004, 306, 636–640.
34. Guillon, N., Tirode, F., Boeva, V., Zynovyev, A., Barillot, E., Delattre, O. The oncogenic EWS-FLI1 protein binds in vivo GGAA microsatellite sequences with potential transcriptional activation function. PLoS ONE 2009, 4, e4932.
35. Bilke, S., Schwentner, R., Yang, F., Kauer, M., Jug, G., Walker, R.L., Davis, S., Zhu, Y.J., Pineda, M., Meltzer, P.S., et al. Oncogenic ets fusions deregulate e2f3 target genes in Ewing sarcoma and prostate cancer. Genome Res. 2013, 23, 1797–1809.
36. Wei, G.-H., Badis, G., Berger, M.F., Kivioja, T., Palin, K., Enge, M., Bonke, M., Jolma, A., Varjosalo, M., Gehrke, A.R., et al. Genome-wide analysis of ets-family DNA-binding in vitro and in vivo. EMBO J. 2010, 29, 2147–2160.
37. Sankar, S., Theisen, E.R., Bearss, J., Mulvihill, T., Hoffman, L.M., Sorna, V., Beckerle, M., Sharma, S., Lessnick, S.L.: Reversible LSD1 inhibition interferes with global EWS/ETS transcriptional activity and impedes Ewing sarcoma tumor growth. Clin. Cancer Res. 2014, 20, doi:10.1158/1078-0432.CCR-14-0072.
38. Marques Howarth, M., Simpson, D., Ngok, S.P., Nieves, B., Chen, R., Siprashvili, Z., Vaka, D., Breese, M.R., Crompton, B.D., Alexe, G., et al. Long noncoding rna ewsat1-mediated gene repression facilitates Ewing sarcoma oncogenesis. J. Clin. Investig. 2014, 124, 5275–5290.
39. Selvanathan, S.P., Graham, G.T., Erkizan, H.V., Dirksen, U., Natarajan, T.G., Dakic, A., Yu, S., Liu, X., Paulsen, M.T., Ljungman, M.E., et al. Oncogenic fusion protein EWS-FLI1 is a network hub that regulates alternative splicing. Proc. Natl. Acad. Sci. USA 2015, 112, E1307–E1316.
40. Erkizan, H.V., Schneider, J.A., Sajwan, K., Graham, G.T., Griffin, B., Chasovskikh, S., Youbi, S.E., Kallarakal, A., Chruszcz, M., Padmanabhan, R., et al. RNA helicase a activity is inhibited by oncogenic transcription factor EWS-FLI 1. Nucleic Acids Res. 2015, 43, 1069–1080.
41. Huang, H.-Y., Illei, P.B., Zhao, Z., Mazumdar, M., Huvos, A.G., Healey, J.H., Wexler, L.H., Gorlick, R., Meyers, P., Ladanyi, M. Ewing sarcomas with p53 mutation or p16/p14arf homozygous deletion: A highly lethal subset associated with poor chemoresponse. J. Clin. Oncol. 2005, 23, 548–558.
42. De Alava, E., Antonescu, C.R., Panizo, A., Leung, D., Meyers, P.A., Huvos, A.G., Pardo-Mindán, F.J., Healey, J.H., Ladanyi, M. Prognostic impact of p53 status in Ewing sarcoma. Cancer 2000, 89, 783–792.
43. Delattre, O., Zucman, J., Plougastel, B., Desmaze, C., Melot, T., Peter, M., Kovar, H., Joubert, I., de Jong, P., Rouleau, G., et al. Gene fusion with an ets DNA-binding domain caused by chromosome translocation in human tumours. Nature 1992, 359, 162–165.
44. Shern, J.F., Chen, L., Chmielecki, J., Wei, J.S., Patidar, R., Rosenberg, M., Ambrogio, L., Auclair, D., Wang, J., Song, Y.K., et al. Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors. Cancer Discov. 2014, 4, 216–231.
45. Ladenstein, R., Pötschger, U., le Deley, M.C., Whelan, J., Paulussen, M., Oberlin, O., van den Berg, H., Dirksen, U., Hjorth, L., Michon, J., et al. Primary disseminated multifocal Ewing sarcoma: Results of the Euro-Ewing 99 trial. J. Clin. Oncol. 2010, 28, 3284–3291.
46. Bacci, G., Ferrari, S., Longhi, A., Donati, D., de Paolis, M., Forni, C., Versari, M., Setola, E., Briccoli, A., Barbieri, E.: Therapy and survival after recurrence of Ewing’s tumors: The rizzoli experience in 195 patients treated with adjuvant and neoadjuvant chemotherapy from 1979 to 1997. Ann. Oncol. 2003, 14, 1654–1659.
47. Hattinger, C.M., Pötschger, U., Tarkkanen, M., Squire, J., Zielenska, M., Kiuru-Kuhlefelt, S., Kager, L., Thorner, P., Knuutila, S., Niggli, F.K., et al. Prognostic impact of chromosomal aberrations in Ewing tumours. Br. J. Cancer 2002, 86, 1763–1769.
48. Mackintosh, C., Ordonez, J.L., Garcia-Dominguez, D.J., Sevillano, V., Llombart-Bosch, A., Szuhai, K., Scotlandi, K., Alberghini, M., Sciot, R., Sinnaeve, F., et al. 1q gain and CDT2 overexpression underlie an aggressive and highly proliferative form of Ewing sarcoma. Oncogene 2012, 31, 1287–1298.
49. Roberts, P., Burchill, S.A., Brownhill, S., Cullinane, C.J., Johnston, C., Griffiths, M.J., McMullan, D.J., Bown, N.P., Morris, S.P., Lewis, I.J.: Ploidy and karyotype complexity are powerful prognostic indicators in the Ewingʼs sarcoma family of tumors: A study by the united kingdom cancer cytogenetics and the childrenʼs cancer and leukaemia group. Genes Chromosomes Cancer 2008, 47, 207–220.
50. Savola, S., Klami, A., Tripathi, A., Niini, T., Serra, M., Picci, P., Kaski, S., Zambelli, D., Scotlandi, K., Knuutila, S.: Combined use of expression and cgh arrays pinpoints novel candidate genes in Ewing sarcoma family of tumors. BMC Cancer 2009, 9, doi:10.1186/1471-2407-9-17
51. Yeh, A., Wei, M., Golub, S.B., Yamashiro, D.J., Murty, V.V., Tycko, B. Chromosome arm 16q in wilms tumors: Unbalanced chromosomal translocations, loss of heterozygosity, and assessment of the ctcf gene. Genes Chromosomes Cancer 2002, 35, 156–163.
52. Mugneret, F., Lizard, S., Aurias, A., Turc-Carel, C. Chromosomes in Ewingʼs sarcoma. II. Nonrandom additional changes, trisomy 8 and der(16)t(1,16). Cancer Genet. Cytogenet. 1988, 32, 239–245.
53. Ozaki, T., Paulussen, M., Poremba, C., Brinkschmidt, C., Rerin, J., Ahrens, S., Hoffmann, C., Hillmann, A., Wai, D., Schaefer, K.-L., et al. Genetic imbalances revealed by comparative genomic hybridization in Ewing tumors. Genes Chromosomes Cancer 2001, 32, 164–171.
54. Gratias, E.J., Jennings, L.J., Anderson, J.R., Dome, J.S., Grundy, P., Perlman, E.J.: Gain of 1q is associated with inferior event-free and overall survival in patients with favorable histology wilms tumor: A report from the children's oncology group. Cancer 2013, 119, 3887–3894.
55. Segers, H., van den Heuvel-Eibrink, M.M., Williams, R.D., van Tinteren, H., Vujanic, G., Pieters, R., Pritchard-Jones, K., Bown, N., on behalf of the Children’s Cancer and Leukaemia Group and the UK Cancer Cytogenetics Group. Gain of 1q is a marker of poor prognosis in wilmsʼ tumors. Genes Chromosomes Cancer 2013, 52, 1065–1074.
56. Terai, K., Shibata, E., Abbas, T., Dutta, A. Degradation of p12 subunit by CRL4Cdt2 E3 ligase inhibits fork progression after DNA damage. J. Biol. Chem. 2013, 288, 30509–30514.
57. Varela, C., Denis, J.A., Polentes, J., Feyeux, M., Aubert, S., Champon, B., Piétu, G., Peschanski, M., Lefort, N. Recurrent genomic instability of chromosome 1q in neural derivatives of human embryonic stem cells. J. Clin. Investig. 2012, 122, 569–574.
58. Sawyer, J.R., Tian, E., Thomas, E., Koller, M., Stangeby, C., Sammartino, G., Goosen, L., Swanson, C., Binz, R.L., Barlogie, B., et al. Evidence for a novel mechanism for gene amplification in multiple myeloma: 1q12 pericentromeric heterochromatin mediates breakage-fusion-bridge cycles of a 1q12~23 amplicon. Br. J. Haematol. 2009, 147, 484–494.
59. Sawyer, J.R., Tricot, G., Mattox, S., Jagannath, S., Barlogie, B. Jumping translocations of chromosome 1q in multiple myeloma: Evidence for a mechanism involving decondensation of pericentromeric heterochromatin. Blood 1998, 91, 1732–1741.
60. Barki-Celli, L., Lefebvre, C., Le Baccon, P., Nadeau, G., Bonnefoix, T., Usson, Y., Vourcʼh, C., Khochbin, S., Leroux, D., Callanan, M. Differences in nuclear positioning of 1q12 pericentric heterochromatin in normal and tumor b lymphocytes with 1q rearrangements. Genes Chromosomes Cancer 2005, 43, 339–349.
61. Baudis, M., Cleary, M.L. Progenetix.net: An online repository for molecular cytogenetic aberration data. Bioinformatics 2001, 17, 1228–1229.
62. Draper, J.S., Smith, K., Gokhale, P., Moore, H.D., Maltby, E., Johnson, J., Meisner, L., Zwaka, T.P., Thomson, J.A., Andrews, P.W. Recurrent gain of chromosomes 17q and 12 in cultured human embryonic stem cells. Nat. Biotechnol. 2004, 22, 53–54
63. Yong, Z.W.E., Zaini, Z.M., Kallarakkal, T.G., Karen-Ng, L.P., Rahman, Z.A.A., Ismail, S.M., Sharifah, N.A., Mustafa, W.M.W., Abraham, M.T., Tay, K.K., et al. Genetic alterations of chromosome 8 genes in oral cancer. Sci. Rep. 2014, 4, doi:10.1038/srep06073.
64. Inaki, K., Menghi, F., Woo, X.Y., Wagner, J.P., Jacques, P.-É., Lee, Y.F., Shreckengast, P.T., Soon, W.W., Malhotra, A., Teo, A.S.M., et al. Systems consequences of amplicon formation in human breast cancer. Genome Res.2014, 24, 1559–1571.
65. Tseng, Y.-Y., Moriarity, B.S., Gong, W., Akiyama, R., Tiwari, A., Kawakami, H., Ronning, P., Reuland, B., Guenther, K., Beadnell, T.C., et al. Pvt1 dependence in cancer with myc copy-number increase. Nature 2014, 512, doi:10.1038/nature13311.
66. Dauphinot, L., De Oliveira, C., Melot, T., Sevenet, N., Thomas, V., Weissman, B.E., Delattre, O. Analysis of the expression of cell cycle regulators in Ewing cell lines: EWS-FLI-1 modulates p57KIP2 and c-Myc. Oncogene 2001, 20, 3258–3265.
67. Ohali, A., Avigad, S., Cohen, I.J., Meller, I., Kollender, Y., Issakov, J., Goshen, Y., Yaniv, I., Zaizov, R. High frequency of genomic instability in Ewing family of tumors. Cancer Genet. Cytogenet. 2004, 150, 50–56.
68. Alldinger, I., Schaefer, K.L., Goedde, D., Ottaviano, L., Dirksen, U., Ranft, A., Juergens, H., Gabbert, H.E., Knoefel, W.T., Poremba, C. Microsatellite instability in Ewing tumor is not associated with loss of mismatch repair protein expression. J. Cancer Res. Clin. Oncol. 2007, 133, 749–759.
69. Lynn, M., Wang, Y., Slater, J., Shah, N., Conroy, J., Ennis, S., Morris, T., Betts, D.R., Fletcher, J.A., O’Sullivan, M.J. High-resolution genome-wide copy-number analyses identify localized copy-number alterations in Ewing sarcoma. Diagn. Mol. Pathol. 2013, 22, 76–84.
70. López-Guerrero, J.A., Machado, I., Scotlandi, K., Noguera, R., Pellín, A., Navarro, S., Serra, M., Calabuig-Fariñas, S., Picci, P., Llombart-Bosch, A. Clinicopathological significance of cell cycle regulation markers in a large series of genetically confirmed Ewingʼs sarcoma family of tumors. Int. J. Cancer 2011, 128, 1139–1150.
71. Ferreira, B.I., Alonso, J., Carrillo, J., Acquadro, F., Largo, C., Suela, J., Teixeira, M.R., Cerveira, N., Molares, A., Gomez-Lopez, G., et al. Array CGH and gene-expression profiling reveals distinct genomic instability patterns associated with DNA repair and cell-cycle checkpoint pathways in Ewingʼs sarcoma. Oncogene 2007, 27, 2084–2090.
72. Solomon, D.A., Kim, J.-S., Bondaruk, J., Shariat, S.F., Wang, Z.-F., Elkahloun, A.G., Ozawa, T., Gerard, J., Zhuang, D., Zhang, S., et al. Frequent truncating mutations of stag2 in bladder cancer. Nat. Genet. 2013, 45, 1428–1430.
73. Solomon, D.A., Kim, T., Diaz-Martinez, L.A., Fair, J., Elkahloun, A.G., Harris, B.T., Toretsky, J.A., Rosenberg, S.A., Shukla, N., Ladanyi, M., et al. Mutational inactivation of stag2 causes aneuploidy in human cancer. Science 2011, 333, 1039–1043.
74. Heidari, N., Phanstiel, D.H., He, C., Grubert, F., Jahanbani, F., Kasowski, M., Zhang, M.Q., Snyder, M.P. Genome-wide map of regulatory interactions in the human genome. Genome Res. 2014, 24, 1905–1917.
75. Tittel-Elmer, M., Lengronne, A., Davidson, M.B., Bacal, J., François, P., Hohl, M., Petrini, J.H.J., Pasero, P., Cobb, J.A. Cohesin association to replication sites depends on rad50 and promotes fork restart. Mol. Cell 2012, 48, 98–108.
76. Bauerschmidt, C., Arrichiello, C., Burdak-Rothkamm, S., Woodcock, M., Hill, M.A., Stevens, D.L., Rothkamm, K. Cohesin promotes the repair of ionizing radiation-induced DNA double-strand breaks in replicated chromatin. Nucleic Acids Res. 2010, 38, 477–487.
77. Ström, L., Lindroos, H.B., Shirahige, K., Sjögren, C. Postreplicative recruitment of cohesin to double-strand breaks is required for DNA repair. Mol. Cell. 2004, 16, 1003–1015.
78. Thota, S., Viny, A.D., Makishima, H., Spitzer, B., Radivoyevitch, T., Przychodzen, B., Sekeres, M.A., Levine, R.L., Maciejewski, J.P. Genetic alterations of the cohesin complex genes in myeloid malignancies. Blood 2014, 124, 1790–1798.
79. Barber, T.D., McManus, K., Yuen, K.W.Y., Reis, M., Parmigiani, G., Shen, D., Barrett, I., Nouhi, Y., Spencer, F., Markowitz, S., et al. Chromatid cohesion defects may underlie chromosome instability in human colorectal cancers. Proc. Natl. Acad. Sci. USA 2008, 105, 3443–3448.
80. Kon, A., Shih, L.-Y., Minamino, M., Sanada, M., Shiraishi, Y., Nagata, Y., Yoshida, K., Okuno, Y., Bando, M., Nakato, R., et al. Recurrent mutations in multiple components of the cohesin complex in myeloid neoplasms. Nat. Genet. 2013, 45, 1232–1237.
81. Taylor, C.F., Platt, F.M., Hurst, C.D., Thygesen, H.H., Knowles, M.A. Frequent inactivating mutations of stag2 in bladder cancer are associated with low tumour grade and stage and inversely related to chromosomal copy number changes. Hum. Mol. Genet. 2014, 23, 1964–1974.
82. Liu, J., Zhang, Z., Bando, M., Itoh, T., Deardorff, M.A., Li, J.R., Clark, D., Kaur, M., Tatsuro, K., Kline, A.D., et al. Genome-wide DNA methylation analysis in cohesin mutant human cell lines. Nucleic Acids Res. 2010, 38, 5657–5671.
83. Neilsen, P.M., Pishas, K.I., Callen, D.F., Thomas, D.M. Targeting the p53 pathway in Ewing sarcoma. Sarcoma 2011, 2011, doi:10.1155/2011/746939.
84. Kovar, H., Auinger, A., Jug, G., Aryee, D., Zoubek, A., Salzer-Kuntschik, M., Gadner, H. Narrow spectrum of infrequent p53 mutations and absence of MDM2 amplification in Ewing tumours. Oncogene 1993, 8, 2683–2690.
85. Olivier, M., Hollstein, M., Hainaut, P. Tp53 mutations in human cancers: Origins, consequences, and clinical use. Cold Spring Harb. Perspect. Biol. 2010, 2, doi:10.1101/cshperspect.a001008.
86. Singh, S.K., Ellenrieder, V. Senescence in pancreatic carcinogenesis: From signalling to chromatin remodelling and epigenetics. Gut 2013, 62, 1364–1372.
87. Ong, C.-T., Corces, V.G. CTCF: An architectural protein bridging genome topology and function. Nat. Rev. Genet. 2014, 15, 234–246.
88. Shukla, N., Ameur, N., Yilmaz, I., Nafa, K., Lau, C.-Y., Marchetti, A., Borsu, L., Barr, F.G., Ladanyi, M.: Oncogen mutation profiling of pediatric solid tumors reveals significant subsets of embryonal rhabdomyosarcoma and neuroblastoma with mutated genes in growth signaling pathways. Clin. Cancer Res. 2012, 18, 748–757.
89. Taiwo, O., Wilson, G.A., Morris, T., Seisenberger, S., Reik, W., Pearce, D., Beck, S., Butcher, L.M. Methylome analysis using medip-seq with low DNA concentrations. Nat. Protoc. 2012, 7, 617–636.
90. Ziller, M.J., Hansen, K.D., Meissner, A., Aryee, M.J. Coverage recommendations for methylation analysis by whole-genome bisulfite sequencing. Nat. Methods 2015, 12, 230–232.
91. Wang, L., Chen, J., Wang, C., Uusküla-Reimand, L., Chen, K., Medina-Rivera, A., Young, E.J., Zimmermann, M.T., Yan, H., Sun, Z., et al. Mace: Model based analysis of chip-exo. Nucleic Acids Res. 2014, 42, doi:10.1093/nar/gku846.
92. Lazarovici, A., Zhou, T., Shafer, A., Dantas Machado, A.C., Riley, T.R., Sandstrom, R., Sabo, P.J., Lu, Y., Rohs, R., Stamatoyannopoulos, J.A., et al. Probing DNA shape and methylation state on a genomic scale with DNase I. Proc. Natl. Acad. Sci. USA 2013, 110, 6376–6381.
93. Vaish, V., Khare, T., Verma, M., Khare, S. Epigenetic Therapy for Colorectal Cancer. In Cancer Epigenetics, Verma, M., Ed., Springer: New York, NY, USA, 2015, Volume 1238, pp. 771–782.
94. Ziller, M.J., Gu, H., Muller, F., Donaghey, J., Tsai, L.T.Y., Kohlbacher, O., de Jager, P.L., Rosen, E.D., Bennett, D.A., Bernstein, B.E., et al. Charting a dynamic DNA methylation landscape of the human genome. Nature 2013, 500, 477–481.
95. Hattori, T., Taft, J.M., Swist, K.M., Luo, H., Witt, H., Slattery, M., Koide, A., Ruthenburg, A.J., Krajewski, K., Strahl, B.D., et al. Recombinant antibodies to histone post-translational modifications. Nat. Methods 2013, 10, 992–995.
96. Rivera, C.M., Ren, B. Mapping human epigenomes. Cell 2013, 155, 39–55.
97. Patel, M., Simon, J.M., Iglesia, M.D., Wu, S.B., McFadden, A.W., Lieb, J.D., Davis, I.J. Tumor-specific retargeting of an oncogenic transcription factor chimera results in dysregulation of chromatin and transcription. Genome Res. 2012, 22, 259–270.
98. Gangwal, K., Sankar, S., Hollenhorst, P.C., Kinsey, M., Haroldsen, S.C., Shah, A.A., Boucher, K.M., Watkins, W.S., Jorde, L.B., Graves, B.J., et al. Microsatellites as EWS/FLI response elements in Ewingʼs sarcoma. Proc. Natl Acad. Sci. USA 2008, 105, 10149–10154.
99. Uchiumi, F., Miyazaki, S., Tanuma, S.-I. Biological functions of the duplicated GGAA-motifs in various human promoter regions (in Japanese). Yakugaku Zasshi 2011, 131, 1787–1800.
100. Hollenhorst, P.C., McIntosh, L.P., Graves, B.J.: Genomic and biochemical insights into the specificity of ets transcription factors. Annu. Rev. Biochem. 2011, 80, 437–471.
101. Sankar, S., Bell, R., Stephens, B., Zhuo, R., Sharma, S., Bearss, D.J., Lessnick, S.L. Mechanism and relevance of EWS/FLI-mediated transcriptional repression in Ewing sarcoma. Oncogene 2013, 32, 5089–5100.
102. Ingram, K.G., Curtis, C.D., Silasi-Mansat, R., Lupu, F., Griffin, C.T. The Nurd chromatin-remodeling enzyme CHD4 promotes embryonic vascular integrity by transcriptionally regulating extracellular matrix proteolysis. PLoS Genet. 2013, 9, e1004031.
103. Liu, J., Wang, H., Ma, F., Xu, D., Chang, Y., Zhang, J., Wang, J., Zhao, M., Lin, C., Huang, C., et al. MTA1 regulates higher-order chromatin structure and histone H1-chromatin interaction in vivo. Mol. Oncol. 2015, 9, 218–235.
104. Conomos, D., Reddel, R.R., Pickett, H.A. Nurd-znf827 recruitment to telomeres creates a molecular scaffold for homologous recombination. Nat. Struct. Mol. Biol. 2014, 21, 760–770.
105. Richter, G.H.S., Plehm, S., Fasan, A., Rössler, S., Unland, R., Bennani-Baiti, I.M., Hotfilder, M., Löwel, D., von Luettichau, I., Mossbrugger, I., et al. Ezh2 is a mediator of EWS/FLI1 driven tumor growth and metastasis blocking endothelial and neuro-ectodermal differentiation. Proc. Natl. Acad. Sci. USA 2009, 106, 5324–5329.
106. Ban, J., Aryee, D.N.T., Fourtouna, A., van der Ent, W., Kauer, M., Niedan, S., Machado, I., Rodriguez-Galindo, C., Tirado, O.M., Schwentner, R., et al. Suppression of deacetylase SIRT1 mediates tumor-suppressive notch response and offers a novel treatment option in metastatic Ewing sarcoma. Cancer Res. 2014, 74, 6578–6588.
107. Park, H.-R., Jung, W.-W., Kim, H.-S., Park, Y.-K. Microarray-based DNA methylation study of Ewing’s sarcoma of the bone. Oncol. Lett. 2014, 8, 1613–1617.
108. Patel, N., Black, J., Chen, X., Marcondes, A.M., Grady, W.M., Lawlor, E.R., Borinstein, S.C. DNA methylation and gene expression profiling of Ewing sarcoma primary tumors reveal genes that are potential targets of epigenetic inactivation. Sarcoma 2012, 2012, doi:10.1155/2012/498472.
109. Ueno, H., Okita, H., Akimoto, S., Kobayashi, K., Nakabayashi, K., Hata, K., Fujimoto, J., Hata, J.-I., Fukuzawa, M., Kiyokawa, N. DNA methylation profile distinguishes clear cell sarcoma of the kidney from other pediatric renal tumors. PLoS ONE 2013, 8, e62233.
110. Petermann, R., Mossier, B.M., Aryee, D.N. Oncogenic EWS-FLI1 interacts with HSRPB7, a subunit of human RNA polymerase II. Oncogene 1998, 17, 603–610.
111. Toretsky, J.A., Erkizan, V., Levenson, A., Abaan, O.D., Parvin, J.D., Cripe, T.P., Rice, A.M., Lee, S.B., Üren, A. Oncoprotein EWS-FLI1 activity is enhanced by RNA helicase A. Cancer Res. 2006, 66, 5574–5581.
112. Rorie, C.J., Thomas, V.D., Chen, P., Pierce, H.H., O’Bryan, J.P., Weissman, B.E. The EWS/FLI-1 fusion gene switches the differentiation program of neuroblastomas to Ewing sarcoma/peripheral primitive neuroectodermal tumors. Cancer Res. 2004, 64, 1266–1277.
113. Hancock, J.D., Lessnick, S.L. A transcriptional profiling meta-analysis reveals a core EWS-FLI gene expression signature. Cell Cycle 2008, 7, 250–256.
114. Prieur, A., Tirode, F., Cohen, P., Delattre, O. EWS/FLI-1 silencing and gene profiling of Ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein 3. Mol. Cell. Biol. 2004, 24, 7275–7283.
115. Smith, R., Owen, L.A., Trem, D.J., Wong, J.S., Whangbo, J.S., Golub, T.R., Lessnick, S.L. Expression profiling of EWS/FLI identifies NKX2.2 as a critical target gene in Ewingʼs sarcoma. Cancer Cell 2006, 9, 405–416.
116. Sáinz-Jaspeado, M., Lagares-Tena, L., Lasheras, J., Navid, F., Rodriguez-Galindo, C., Mateo-Lozano, S., Notario, V., Sanjuan, X., Garcia del Muro, X., Fabra, À., et al. Caveolin-1 modulates the ability of Ewingʼs sarcoma to metastasize. Mol. Cancer Res. 2010, 8, 1489–1500.
117. Herrero-Martin, D., Osuna, D., Ordonez, J.L., Sevillano, V., Martins, A.S., Mackintosh, C., Campos, M., Madoz-Gurpide, J., Otero-Motta, A.P., Caballero, G., et al. Stable interference of EWS-FLI1 in an Ewing sarcoma cell line impairs IGF-1/IGF-1R signalling and reveals TOPK as a new target. Br. J. Cancer 2009, 101, 80–90.
118. Grunewald, T.G.P., Ranft, A., Esposito, I., da Silva-Buttkus, P., Aichler, M., Baumhoer, D., Schaefer, K.L., Ottaviano, L., Poremba, C., Jundt, G., et al. High steap1 expression is associated with improved outcome of Ewingʼs sarcoma patients. Ann. Oncol. 2012, 23, 2185–2190.
119. Richter, G.H.S., Fasan, A., Hauer, K., Grunewald, T.G.P., Berns, C., Rössler, S., Naumann, I., Staege, M.S., Fulda, S., Esposito, I., et al. G-protein coupled receptor 64 promotes invasiveness and metastasis in Ewing sarcomas through PGF and MMP 1. J. Pathol. 2013, 230, 70–81.
120. Rocchi, A., Manara, M.C., Sciandra, M., Zambelli, D., Nardi, F., Nicoletti, G., Garofalo, C., Meschini, S., Astolfi, A., Colombo, M.P., et al. Cd99 inhibits neural differentiation of human Ewing sarcoma cells and thereby contributes to oncogenesis. J. Clin. Investig. 2010, 120, 668–680.
121. Staege, M.S., Hutter, C., Neumann, I., Foja, S., Hattenhorst, U.E., Hansen, G., Afar, D., Burdach, S.E.G. DNA microarrays reveal relationship of Ewing family tumors to both endothelial and fetal neural crest-derived cells and define novel targets. Cancer Res. 2004, 64, 8213–8221.
122. Grunewald, T.G.P., Diebold, I., Esposito, I., Plehm, S., Hauer, K., Thiel, U., da Silva-Buttkus, P., Neff, F., Unland, R., Müller-Tidow, C., et al. Steap1 is associated with the invasive and oxidative stress phenotype of Ewing tumors. Mol. Cancer Res. 2012, 10, 52–65.
123. Wiles, E.T., Lui-Sargent, B., Bell, R., Lessnick, S.L. Bcl11b is up-regulated by EWS/FLI and contributes to the transformed phenotype in Ewing sarcoma. PLoS ONE 2013, 8, e59369.
124. Joo, J., Christensen, L., Warner, K., States, L., Kang, H.-G., Vo, K., Lawlor, E.R., May, W.A. Gli1 is a central mediator of EWS/FLI1 signaling in Ewing tumors. PLoS ONE 2009, 4, e7608.
125. Kinsey, M., Smith, R., Lessnick, S.L. Nr0b1 is required for the oncogenic phenotype mediated by EWS/FLI in Ewingʼs sarcoma. Mol. Cancer Res. 2006, 4, 851–859.
126. Schwentner, R., Papamarkou, T., Kauer, M.O., Stathopoulos, V., Yang, F., Bilke, S., Meltzer, P.S., Girolami, M., Kovar, H. EWS-FLI1 employs an e2f switch to drive target gene expression. Nucleic Acids Res. 2015, 43, doi:10.1093/nar/gkv123.
127. Fuchs, B., Inwards, C.Y., Janknecht, R. Vascular endothelial growth factor expression is up-regulated by EWS-ETS oncoproteins and sp1 and may represent an independent predictor of survival in Ewing’s sarcoma. Clin. Cancer Res. 2004, 10, 1344–1353.
128. Karnuth, B., Dedy, N., Spieker, T., Lawlor, E.R., Gattenlöhner, S., Ranft, A., Dirksen, U., Jürgens, H., Bräuninger, A. Differentially expressed mirnas in Ewing sarcoma compared to mesenchymal stem cells: Low miR-31 expression with effects on proliferation and invasion. PLoS ONE 2014, 9, e93067.
129. Friedman, R.C., Farh, K.K.-H., Burge, C.B., Bartel, D.P. Most mammalian mRNAs are conserved targets of MicroRNAs. Genome Res. 2009, 19, 92–105.
130. Ban, J., Jug, G., Mestdagh, P., Schwentner, R., Kauer, M., Aryee, D.N.T., Schaefer, K.L., Nakatani, F., Scotlandi, K., Reiter, M., et al. Hsa-miR-145 is the top EWS-FLI1-repressed microRNA involved in a positive feedback loop in Ewingʼs sarcoma. Oncogene 2011, 30, 2173–2180.
131. De Vito, C., Riggi, N., Suvà, M.-L., Janiszewska, M., Horlbeck, J., Baumer, K., Provero, P., Stamenkovic, I. Let-7a is a direct EWS-FLI-1 target implicated in Ewingʼs sarcoma development. PLoS ONE 2011, 6, e23592.
132. Robin, T.P., Smith, A., McKinsey, E., Reaves, L., Jedlicka, P., Ford, H.L. EWS/FLI1 regulates EYA3 in Ewing sarcoma via modulation of miRNA-708, resulting in increased cell survival and chemoresistance. Mol. Cancer Res. 2012, 10, 1098–1108.
133. McKinsey, E.L., Parrish, J.K., Irwin, A.E., Niemeyer, B.F., Kern, H.B., Birks, D.K., Jedlicka, P. A novel oncogenic mechanism in Ewing sarcoma involving IGF pathway targeting by EWS/FLI1-regulated micrornas. Oncogene 2011, 30, 4910–4920.
134. Parrish, J.K., Sechler, M., Winn, R.A., Jedlicka, P. The histone demethylase KDM3A is a microRNA-22-regulated tumor promoter in Ewing sarcoma. Oncogene 2015, 34, 257–262.
135. Nakatani, F., Ferracin, M., Manara, M.C., Ventura, S., del Monaco, V., Ferrari, S., Alberghini, M., Grilli, A., Knuutila, S., Schaefer, K.-L., et al. MiR-34a predicts survival of Ewingʼs sarcoma patients and directly influences cell chemo-sensitivity and malignancy. J. Pathol. 2012, 226, 796–805.
136. Bommer, G.T., Gerin, I., Feng, Y., Kaczorowski, A.J., Kuick, R., Love, R.E., Zhai, Y., Giordano, T.J., Qin, Z.S., Moore, B.B., et al. P53-mediated activation of miRNA34 candidate tumor-suppressor genes. Curr. Biol. 2007, 17, 1298–1307.
137. Ferreira, D.M.S., Afonso, M.B., Rodrigues, P.M., Simão, A., Pereira, D.M., Borralho, P.M., Rodrigues, C.M.P., Castro, R.E. JNK1/c-Jun-activation of the p53/miRNA-34a/sirtuin1 pathway contributes to apoptosis induced by deoxycholic acid in rat liver. Mol. Cell. Biol. 2014, 34, 1100–1120.
138. Rathod, S.S., Rani, S.B., Khan, M., Muzumdar, D., Shiras, A. Tumor suppressive miRNA-34a suppresses cell proliferation and tumor growth of glioma stem cells by targeting Akt and Wnt signaling pathways. FEBS Open Biol. 2014, 4, 485–495.
139. Quinodoz, S., Guttman, M. Long noncoding RNAs: An emerging link between gene regulation and nuclear organization. Trends Cell. Biol. 2014, 24, 651–663.
140. Hudson, W.H., Ortlund, E.A. The structure, function and evolution of proteins that bind DNA and RNA. Nat. Rev. Mol. Cell. Biol. 2014, 15, 749–760.
141. Michalik, K.M., You, X., Manavski, Y., Doddaballapur, A., Zörnig, M., Braun, T., John, D., Ponomareva, Y., Chen, W., Uchida, S., et al. The long noncoding RNA malat1 regulates endothelial cell function and vessel growth. Circ. Res. 2014, 114, 1389–1397.
142. Wang, J., Wang, H., Zhang, Y., Zhen, N., Zhang, L., Qiao, Y., Weng, W., Liu, X., Ma, L., Xiao, W., et al. Mutual inhibition between YAP and SRSF1 maintains long non-coding RNA, Malat1-induced tumourigenesis in liver cancer. Cell Signal. 2014, 26, 1048–1059.
143. Brunner, A.L., Beck, A.H., Edris, B., Sweeney, R.T., Zhu, S.X., Li, R., Montgomery, K., Varma, S., Gilks, T., Guo, X., et al. Transcriptional profiling of long non-coding RNAs and novel transcribed regions across a diverse panel of archived human cancers. Genome Biol. 2012, 13, doi:10.1186/gb-2012-13-8-r75.
144. Fu, X.-D., Ares, M., Jr. Context-dependent control of alternative splicing by RNA-binding proteins. Nat. Rev. Genet. 2014, 15, 689–701.
145. Paronetto, M.P., Miñana, B., Valcárcel, J. The Ewing sarcoma protein regulates DNA damage-induced alternative splicing. Mol. Cell 2011, 43, 353–368.
146. Yang, L., Chansky, H.A., Hickstein, D.D. EWS·FLI-1 fusion protein interacts with hyperphosphorylated RNA polymerase II and interferes with serine-arginine protein-mediated RNA splicing. J. Biol. Chem. 2000, 275, 37612–37618.
147. Knoop, L.L., Baker, S.J. The splicing factor U1C represses EWS/FLI-mediated transactivation. J. Biol. Chem. 2000, 275, 24865–24871.
148. Knoop, L.L., Baker, S.J.: EWS/FLI alters 5′-splice site selection. J. Biol. Chem. 2001, 276, 22317–22322.
149. Jain, A., Bacolla, A., del Mundo, I.M., Zhao, J., Wang, G., Vasquez, K.M. Dhx9 helicase is involved in preventing genomic instability induced by alternatively structured DNA in human cells. Nucleic Acids Res. 2013, 41, 10345–10357.
150. Sanchez, G., Delattre, O., Auboeuf, D., Dutertre, M.: Coupled alteration of transcription and splicing by a single oncogene: Boosting the effect on cyclin D1 activity. Cell.Cycle 2008, 7, 2299–2305.
151. Huang, G., Zhou, Z., Wang, H., Kleinerman, E.S. Caper-α alternative splicing regulates the expression of vascular endothelial growth factor165 in Ewing sarcoma cells. Cancer 2012, 118, 2106–2116.
152. Ewing, J. Diffuse endothelioma of bone Proc. N. Y. Path. Soc. 1921, 21, doi:10.3322/canjclin.22.2.95.
153. Jenkin, R.D.T. Ewing’s sarcoma a study of treatment methods. Clin. Radiol. 1966, 17, 97–106.
154. Balamuth, N.J., Womer, R.B. Ewingʼs sarcoma. Lancet Oncol. 2010, 11, 184–192.
155. Womer, R.B., West, D.C., Krailo, M.D., Dickman, P.S., Pawel, B.R., Grier, H.E., Marcus, K., Sailer, S., Healey, J.H., Dormans, J.P., et al. Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: A report from the childrenʼs oncology group. J. Clin. Oncol. 2012, 30, 4148–4154.
156. Ginsberg, J.P., Goodman, P., Leisenring, W., Ness, K.K., Meyers, P.A., Wolden, S.L., Smith, S.M., Stovall, M., Hammond, S., Robison, L.L., et al. Long-term survivors of childhood Ewing sarcoma: Report from the childhood cancer survivor study. J. Natl. Cancer Inst. 2010, 102, 1272–1283.
157. Van Maldegem, A.M., Hogendoorn, P.C.W., Hassan, A.B. The clinical use of biomarkers as prognostic factors in Ewing sarcoma. Clin. Sarcoma Res. 2012, 2, doi:10.1186/2045-3329-2-7.
158. Ludwig, J.A.: Ewing sarcoma: Historical perspectives, current state-of-the-art, and opportunities for targeted therapy in the future. Curr. Opin. Oncol. 2008, 20, 412–418.
159. Grier, H.E., Krailo, M.D., Tarbell, N.J., Link, M.P., Fryer, C.J.H., Pritchard, D.J., Gebhardt, M.C., Dickman, P.S., Perlman, E.J., Meyers, P.A., et al. Addition of ifosfamide and etoposide to standard chemotherapy for Ewingʼs sarcoma and primitive neuroectodermal tumor of bone. N. Engl. J. Med. 2003, 348, 694–701.
160. Granowetter, L., Womer, R., Devidas, M., Krailo, M., Wang, C., Bernstein, M., Marina, N., Leavey, P., Gebhardt, M., Healey, J., et al. Dose-intensified compared with standard chemotherapy for nonmetastatic Ewing sarcoma family of tumors: A childrenʼs oncology group study. J. Clin. Oncol. 2009, 27, 2536–2541.
161. Brenner, J.C., Feng, F.Y., Han, S., Patel, S., Goyal, S.V., Bou-Maroun, L.M., Liu, M., Lonigro, R., Prensner, J.R., Tomlins, S.A., et al. Parp-1 inhibition as a targeted strategy to treat Ewingʼs sarcoma. Cancer Res. 2012, 72, 1608–1613.
162. Stewart, E., Goshorn, R., Bradley, C., Griffiths Lyra, M., Benavente, C., Twarog, Nathaniel R., Miller Gregory, M., Caufield, W., Freeman, Burgess B., Bahrami, A., et al.: Targeting the DNA repair pathway in Ewing sarcoma. Cell Rep. 2014, 9, 829–840.
163. Smith, M.A., Reynolds, C.P., Kang, M.H., Kolb, E.A., Gorlick, R., Carol, H., Lock, R.B., Keir, S.T., Maris, J.M., Billups, C.A., et al. Synergistic activity of PARP inhibition by talazoparib (BMN 673) with temozolomide in pediatric cancer models in the pediatric preclinical testing program. Clin. Cancer Res. 2015, 21, 819–832.
164. Choy, E., Butrynski, J., Harmon, D., Morgan, J., George, S., Wagner, A., DʼAdamo, D., Cote, G., Flamand, Y., Benes, C., et al. Phase II study of olaparib in patients with refractory Ewing sarcoma following failure of standard chemotherapy. BMC Cancer 2014, 14, doi:10.1186/1471-2407-14-813.
165. Tahara, M., Inoue, T., Sato, F., Miyakura, Y., Horie, H., Yasuda, Y., Fujii, H., Kotake, K., Sugano, K. The use of olaparib (AZD2281) potentiates SN-38 cytotoxicity in colon cancer cells by indirect inhibition of Rad51-mediated repair of DNA double-strand breaks. Mol. Cancer Ther. 2014, 13, 1170–1180.
166. McCabe, N., Turner, N.C., Lord, C.J., Kluzek, K., Białkowska, A., Swift, S., Giavara, S., OʼConnor, M.J., Tutt, A.N., Zdzienicka, M.Z., et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res. 2006, 66, 8109–8115.
167. Bailey, M.L., OʼNeil, N.J., van Pel, D.M., Solomon, D.A., Waldman, T., Hieter, P. Glioblastoma cells containing mutations in the cohesin component STAG2 are sensitive to PARP inhibition. Mol. Cancer Ther. 2014, 13, 724–732.
168. Norris, R.E., Adamson, P.C., Nguyen, V.T., Fox, E. Preclinical evaluation of the PARP inhibitor, olaparib, in combination with cytotoxic chemotherapy in pediatric solid tumors. Pediatr. Blood Cancer 2014, 61, 145–150.
169. Chen, C., Wonsey, D.R., Lemieux, M.E., Kung, A.L. Differential disruption of EWS-FLI1 binding by DNA-binding agents. PLoS ONE 2013, 8, e69714.
170. Smith, M.A., Ungerleider, R.S., Horowitz, M.E., Simon, R. Influence of doxorubicin dose intensity on response and outcome for patients with osteogenic sarcoma and Ewingʼs sarcoma. J. Natl. Cancer Inst. 1991, 83, 1460–1470.
171. Di Giandomenico, S., Frapolli, R., Bello, E., Uboldi, S., Licandro, S.A., Marchini, S., Beltrame, L., Brich, S., Mauro, V., Tamborini, E., et al. Mode of action of trabectedin in myxoid liposarcomas. Oncogene 2014, 33, 5201–5210.
172. Baruchel, S., Pappo, A., Krailo, M., Baker, K.S., Wu, B., Villaluna, D., Lee-Scott, M., Adamson, P.C., Blaney, S.M.: A phase 2 trial of trabectedin in children with recurrent rhabdomyosarcoma, Ewing sarcoma and non-rhabdomyosarcoma soft tissue sarcomas: A report from the children’s oncology group. Eur. J. Cancer 2012, 48, 579–585.
173. Bennani-Baiti, I.M., Machado, I., Llombart-Bosch, A., Kovar, H. Lysine-specific demethylase 1 (LSD1/KDM1A/AOF2/BHC110) is expressed and is an epigenetic drug target in chondrosarcoma, Ewing’s sarcoma, osteosarcoma, and rhabdomyosarcoma. Hum. Pathol. 2012, 43, 1300–1307.
174. Sakimura, R., Tanaka, K., Nakatani, F., Matsunobu, T., Li, X., Hanada, M., Okada, T., Nakamura, T., Matsumoto, Y., Iwamoto, Y. Antitumor effects of histone deacetylase inhibitor on Ewingʼs family tumors. Int. J. Cancer 2005, 116, 784–792.
175. Owen, L.A., Kowalewski, A.A., Lessnick, S.L. EWS/FLI mediates transcriptional repression via NKX2.2 during oncogenic transformation in Ewingʼs sarcoma. PLoS ONE 2008, 3, e1965.
176. Ng, K.P., Potikyan, G., Savene, R.O.V., Denny, C.T., Uversky, V.N., Lee, K.A.W. Multiple aromatic side chains within a disordered structure are critical for transcription and transforming activity of ews family oncoproteins. Proc. Natl. Acad. Sci. USA 2007, 104, 479–484.
177. Erkizan, H.V., Kong, Y., Merchant, M., Schlottmann, S., Barber-Rotenberg, J.S., Yuan, L., Abaan, O.D., Chou, T.-H., Dakshanamurthy, S., Brown, M.L., et al. A small molecule blocking oncogenic protein EWS-FLI1 interaction with rna helicase a inhibits growth of Ewingʼs sarcoma. Nat. Med. 2009, 15, 750–756.
178. Tosso, P.N., Kong, Y., Scher, L., Cummins, R., Schneider, J., Rahim, S., Holman, K.T., Toretsky, J., Wang, K., Üren, A., et al. Synthesis and structure-activity relationship studies of small molecule disruptors of EWS-FLI1 interactions in Ewing’s sarcoma. J. Med. Chem. 2014, 57, 10290–10303.
179. Van der Ent, W., Jochemsen, A.G., Teunisse, A.F.A.S., Krens, S.F.G., Szuhai, K., Spaink, H.P., Hogendoorn, P.C.W., Snaar-Jagalska, B.E.: Ewing sarcoma inhibition by disruption of EWSR1-FLI1 transcriptional activity and reactivation of p 53. J. Pathol. 2014, 233, 415–424.
180. Hanahan, D. Weinberg, Robert A. Hallmarks of cancer: The next generation. Cell 2011, 144, 646–674.
181. Seccareccia, E., Brodt, P. The role of the insulin-like growth factor-I receptor in malignancy: An update. Growth Horm. IGF Res. 2012, 22, 193–199.
182. Rapraeger, A.C.: Synstatin: A selective inhibitor of the syndecan-1-coupled IGF1R-αvβ3 integrin complex in tumorigenesis and angiogenesis. FEBS J. 2013, 280, 2207–2215.
183. Mulvihill, M.J., Cooke, A., Rosenfeld-Franklin, M., Buck, E., Foreman, K., Landfair, D., O’Connor, M., Pirritt, C., Sun, Y., Yao, Y., et al. Discovery of OSI-906: A selective and orally efficacious dual inhibitor of the IGF-1 receptor and insulin receptor. Future Med. Chem. 2009, 1, 1153–1171.
184. Kurmasheva, R.T., Dudkin, L., Billups, C., Debelenko, L.V., Morton, C.L., Houghton, P.J. The insulin-like growth factor-1 receptor-targeting antibody, CP-751,871, suppresses tumor-derived VEGF and synergizes with rapamycin in models of childhood sarcoma. Cancer Res. 2009, 69, 7662–7671.
185. Ackermann, M., Morse, B., Delventhal, V., Carvajal, I., Konerding, M. Anti-VEGFR2 and anti-IGF-1R-adnectins inhibit Ewing’s sarcoma A673-xenograft growth and normalize tumor vascular architecture. Angiogenesis 2012, 15, 685–695.
186. Pappo, A.S., Vassal, G., Crowley, J.J., Bolejack, V., Hogendoorn, P.C.W., Chugh, R., Ladanyi, M., Grippo, J.F., Dall, G., Staddon, A.P., et al. A phase 2 trial of R1507, a monoclonal antibody to the insulin-like growth factor-1 receptor (IGF-1R), in patients with recurrent or refractory rhabdomyosarcoma, osteosarcoma, synovial sarcoma, and other soft tissue sarcomas: Results of a sarcoma alliance for research through collaboration study. Cancer 2014, 120, 2448–2456.
187. Schöffski, P., Adkins, D., Blay, J.Y., Gil, T., Elias, A.D., Rutkowski, P., Pennock, G.K., Youssoufian, H., Gelderblom, H., Willey, R., et al. An open-label, phase 2 study evaluating the efficacy and safety of the anti-IGF-1R antibody cixutumumab in patients with previously treated advanced or metastatic soft-tissue sarcoma or Ewing family of tumours. Eur. J. Cancer 2013, 49, 3219–3228.
188. Amaral, A.T., Garofalo, C., Frapolli, R., Manara, M.C., Mancarella, C., Uboldi, S., di Giandomenico, S., Ordóñez, J.L., Sevillano, V., Malaguarnera, R., et al. Trabectedin efficacy in Ewing sarcoma is greatly increased by combination with anti-IGF signaling agents. Clin. Cancer Res. 2015, 21, 1373–1382.
189. Zhao, Y., Adjei, A.A. Targeting angiogenesis in cancer therapy: Moving beyond vascular endothelial growth factor. Oncologist 2015, 20, 660–673.
190. Reddy, K., Zhou, Z., Jia, S.-F., Lee, T.H., Morales-Arias, J., Cao, Y., Kleinerman, E.S.: Stromal cell-derived factor-1 stimulates vasculogenesis and enhances Ewingʼs sarcoma tumor growth in the absence of vascular endothelial growth factor. Int. J. Cancer 2008, 123, 831–837.
191. Zhou, Z., Yu, L., Kleinerman, E.S. EWS-FLI-1 regulates the neuronal repressor gene rest, which controls Ewing sarcoma growth and vascular morphology. Cancer 2014, 120, 579–588.
192. DuBois, S.G., Marina, N., Glade-Bender, J. Angiogenesis and vascular targeting in Ewing sarcoma. Cancer 2010, 116, 749–757.
193. Wagner, L., Turpin, B., Nagarajan, R., Weiss, B., Cripe, T., Geller, J.: Pilot study of vincristine, oral irinotecan, and temozolomide (voit regimen) combined with bevacizumab in pediatric patients with recurrent solid tumors or brain tumors. Pediatr. Blood Cancer 2013, 60, 1447–1451.
194. Hillen, F., Kaijzel, E.L., Castermans, K., Egbrink, M.G.A.O., Löwik, C.W.G.M., Griffioen, A.W. A transgenic TIE2-GFP athymic mouse model, a tool for vascular biology in xenograft tumors. Biochem. Biophys. Res. Commun. 2008, 368, 364–367.
195. Van der Schaft, D.W.J., Hillen, F., Pauwels, P., Kirschmann, D.A., Castermans, K., Oude Egbrink, M.G.A., Tran, M.G.B., Sciot, R., Hauben, E., Hogendoorn, P.C.W., et al. Tumor cell plasticity in Ewing sarcoma, an alternative circulatory system stimulated by hypoxia. Cancer Res. 2005, 65, 11520–11528.
196. Pardali, E., van der Schaft, D.W.J., Wiercinska, E., Gorter, A., Hogendoorn, P.C.W., Griffioen, A.W., ten Dijke, P. Critical role of endoglin in tumor cell plasticity of Ewing sarcoma and melanoma. Oncogene 2011, 30, 334–345.
197. Mantovani, A., Savino, B., Locati, M., Zammataro, L., Allavena, P., Bonecchi, R. The chemokine system in cancer biology and therapy. Cytokine Growth Factor Rev. 2010, 21, 27–39.
198. Berghuis, D., Santos, S.J., Baelde, H.J., Taminiau, A.H.M., Maarten Egeler, R., Schilham, M.W., Hogendoorn, P.C.W., Lankester, A.C. Pro-inflammatory chemokine-chemokine receptor interactions within the Ewing sarcoma microenvironment determine CD8+ T-lymphocyte infiltration and affect tumour progression. J. Pathol. 2011, 223, 347–357.
199. Lissat, A., Vraetz, T., Tsokos, M., Klein, R., Braun, M., Koutelia, N., Fisch, P., Romero, M.E., Long, L., Noellke, P., et al. Interferon-γ sensitizes resistant Ewing’s sarcoma cells to tumor necrosis factor apoptosis-inducing ligand-induced apoptosis by up-regulation of caspase-8 without altering chemosensitivity. Am. J. Pathol. 2007, 170, 1917–1930.
200. Bennani-Baiti, I.M., Cooper, A., Lawlor, E.R., Kauer, M., Ban, J., Aryee, D.N.T., Kovar, H. Intercohort gene expression co-analysis reveals chemokine receptors as prognostic indicators in Ewingʼs sarcoma. Clin. Cancer Res. 2010, 16, 3769–3778.
201. Domanska, U.M., Kruizinga, R.C., Nagengast, W.B., Timmer-Bosscha, H., Huls, G., de Vries, E.G.E., Walenkamp, A.M.E. A review on CXCR4/CXCL12 axis in oncology: No place to hide. Eur. J. Cancer 2013, 49, 219–230.
202. Lippitz, B.E. Cytokine patterns in patients with cancer: A systematic review. Lancet Oncol. 2013, 14, e218–e228.
203. Brennecke, P., Arlt, M.E., Campanile, C., Husmann, K., Gvozdenovic, A., Apuzzo, T., Thelen, M., Born, W., Fuchs, B. CXCR4 antibody treatment suppresses metastatic spread to the lung of intratibial human osteosarcoma xenografts in mice. Clin. Exp. Metastasis 2014, 31, 339–349.
204. Krook, M.A., Nicholls, L.A., Scannell, C.A., Chugh, R., Thomas, D.G., Lawlor, E.R.: Stress-induced CXCR4 promotes migration and invasion of Ewing sarcoma. Mol. Cancer Res. 2014, 12, 953–964.
205. Berghuis, D., Schilham, M.W., Santos, S.J., Savola, S., Knowles, H.J., Dirksen, U., Schaefer, K.-L., Vakkila, J., Hogendoorn, P.C.W., Lankester, A.C. The CXCR4-CXCL12 axis in Ewing sarcoma: Promotion of tumor growth rather than metastatic disease. Clin. Sarcoma Res. 2012, 2, doi:10.1186/2045-3329-2-24.
206. Gupta, S.K., Pillarisetti, K. Cutting edge: CXCR4-LO: Molecular cloning and functional expression of a novel human cxcr4 splice variant. J. Immunol. 1999, 163, 2368–2372.
207. Farzan, M., Babcock, G.J., Vasilieva, N., Wright, P.L., Kiprilov, E., Mirzabekov, T., Choe, H. The role of post-translational modifications of the cxcr4 amino terminus in stromal-derived factor 1α association and HIV-1 entry. J. Biol. Chem. 2002, 277, 29484–29489.
208. Zhou, N., Luo, Z., Luo, J., Liu, D., Hall, J.W., Pomerantz, R.J., Huang, Z. Structural and functional characterization of human cxcr4 as a chemokine receptor and HIV-1 co-receptor by mutagenesis and molecular modeling studies. J. Biol. Chem. 2001, 276, 42826–42833.
209. Rapp, C., Snow, S., Laufer, T., McClendon, C.L. The role of tyrosine sulfation in the dimerization of the CXCR4:SDF-1 complex. Protein Sci. 2013, 22, 1025–1036.
210. Chabot, D.J., Chen, H., Dimitrov, D.S., Broder, C.C. N-linked glycosylation of CXCR4 masks coreceptor function for CCR5-dependent human immunodeficiency virus type 1 isolates. J. Virol. 2000, 74, 4404–4413.
211. Stoll, G., Surdez, D., Tirode, F., Laud, K., Barillot, E., Zinovyev, A., Delattre, O. Systems biology of Ewing sarcoma: A network model of EWS-FLI1 effect on proliferation and apoptosis. Nucleic Acids Res. 2013, 41, 8853–8871.
212. Vakkila, J., Jaffe, R., Michelow, M., Lotze, M.T.: Pediatric cancers are infiltrated predominantly by macrophages and contain a paucity of dendritic cells: A major nosologic difference with adult tumors. Clin. Cancer Res. 2006, 12, 2049–2054.
213. Verhoeven, D.H.J., de Hooge, A.S.K., Mooiman, E.C.K., Santos, S.J., ten Dam, M.M., Gelderblom, H., Melief, C.J.M., Hogendoorn, P.C.W., Egeler, R.M., van Tol, M.J.D., et al. NK cells recognize and lyse Ewing sarcoma cells through NKG2D and DNAM-1 receptor dependent pathways. Mol. Immunol. 2008, 45, 3917–3925.
214. Cho, D., Shook, D.R., Shimasaki, N., Chang, Y.-H., Fujisaki, H., Campana, D. Cytotoxicity of activated natural killer cells against pediatric solid tumors. Clin. Cancer Res. 2010, 16, 3901–3909.
215. Berghuis, D., Schilham, M.W., Vos, H.I., Santos, S.J., Kloess, S., Buddingh, E.P., Egeler, R.M., Hogendoorn, P.C.W., Lankester, A.C. Histone deacetylase inhibitors enhance expression of NKG2D ligands in Ewing sarcoma and sensitize for natural killer cell-mediated cytolysis. Clin. Sarcoma Res. 2012, 2, doi:10.1186/2045-3329-2-8.
216. Pahl, J.W., Ruslan, S.E., Kwappenberg, K.C., van Ostaijen-ten Dam, M., van Tol, M.D., Lankester, A., Schilham, M. Antibody-dependent cell lysis by NK cells is preserved after sarcoma-induced inhibition of nk cell cytotoxicity. Cancer Immunol. Immunother. 2013, 62, 1235–1247.
217. Goodison, S., Urquidi, V. The cancer testis antigen prame as a biomarker for solid tumor cancer management. Biomark. Med. 2012, 6, 629–632.
218. Osterhoff, C., Ivell, R., Kirchhoff, C. Cloning of a human epididymis-specific mRNA, HE6, encoding a novel member of the seven transmembrane-domain receptor superfamily. DNA Cell. Biol. 1997, 16, 379–389.
219. Moreaux, J., Kassambara, A., Hose, D., Klein, B. Steap1 is overexpressed in cancers: A promising therapeutic target. Biochem. Biophys. Res. Commun. 2012, 429, 148–155.
220. Altvater, B., Kailayangiri, S., Theimann, N., Ahlmann, M., Farwick, N., Chen, C., Pscherer, S., Neumann, I., Mrachatz, G., Hansmeier, A., et al. Common Ewing sarcoma-associated antigens fail to induce natural T cell responses in both patients and healthy individuals. Cancer Immunol. Immunother. 2014, 63, 1047–1060.
221. Thiel, U., Pirson, S., Muller-Spahn, C., Conrad, H., Busch, D.H., Bernhard, H., Burdach, S., Richter, G.H.S.: Specific recognition and inhibition of Ewing tumour growth by antigen-specific allo-restricted cytotoxic t cells. Br. J. Cancer 2011, 104, 948–956.
222. Evans, C.H., Liu, F., Porter, R.M., OʼSullivan, R.P., Merghoub, T., Lunsford, E.P., Robichaud, K., van Valen, F., Lessnick, S.L., Gebhardt, M.C., et al. EWS-FLI-1-targeted cytotoxic T-cell killing of multiple tumor types belonging to the Ewing sarcoma family of tumors. Clin. Cancer Res. 2012, 18, 5341–5351.
223. Berghuis, D., de Hooge, A.S.K., Santos, S.J., Horst, D., Wiertz, E.J., van Eggermond, M.C., van den Elsen, P.J., Taminiau, A.H.M., Ottaviano, L., Schaefer, K.-L., et al. Reduced human leukocyte antigen expression in advanced-stage Ewing sarcoma: Implications for immune recognition. J. Pathol. 2009, 218, 222–231.
224. Liebsch, L., Kailayangiri, S., Beck, L., Altvater, B., Koch, R., Dierkes, C., Hotfilder, M., Nagelmann, N., Faber, C., Kooijman, H., et al. Ewing sarcoma dissemination and response to T-cell therapy in mice assessed by whole-body magnetic resonance imaging. Br. J. Cancer 2013, 109, 658–666.
225. Kailayangiri, S., Altvater, B., Meltzer, J., Pscherer, S., Luecke, A., Dierkes, C., Titze, U., Leuchte, K., Landmeier, S., Hotfilder, M., et al. The ganglioside antigen GD2 is surface-expressed in Ewing sarcoma and allows for MHC-independent immune targeting. Br. J. Cancer 2012, 106, 1123–1133
226. Dominici, M., Le Blanc, K., Mueller, I., Slaper-Cortenbach, I., Marini, F.C., Krause, D.S., Deans, R.J., Keating, A., Prockop, D.J., Horwitz, E.M. Minimal criteria for defining multipotent mesenchymal stromal cells. The international society for cellular therapy position statement. Cytotherapy 2006, 8, 315–317.
227. Martinez, C., Hofmann, T.J., Marino, R., Dominici, M., Horwitz, E.M. Human bone marrow mesenchymal stromal cells express the neural ganglioside GD2: A novel surface marker for the identification of MSCs. Blood 2007, 109, 4245–4248.